Literature DB >> 11950822

Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin.

T Zolfino1, M A Heneghan, S Norris, P M Harrison, B C Portmann, I G McFarlane.   

Abstract

BACKGROUND: Significant diversity in disease severity has been identified for autoimmune disorders among different ethnic groups but there is a lack of data on autoimmune hepatitis (AIH) in populations other than those of European Caucasoid (EC) or Japanese extraction. AIMS: To assess the clinical features, response to therapy, and eventual outcome in AIH patients of non-EC ethnicity.
METHODS: A retrospective review of a regularly updated database of patients with AIH referred to liver outpatient clinics at King's College Hospital, London, since 1983.
RESULTS: Twelve patients were identified (10 female; six African, five Asian, one Arabic; median age at presentation 30 years (range 12-58)) who satisfied international criteria for type 1 (11 cases) or type 2 (one case) AIH. Nine (75%) had cholestatic serum biochemistry and three (25%) had mild biliary changes on liver biopsy without definitive features of primary biliary cirrhosis or cholangiographic evidence of primary sclerosing cholangitis. Four showed a complete biochemical response to standard prednisolone with or without azathioprine therapy, three partial, and five no response. Four have required liver transplantation for intractable disease. By comparison with 180 EC patients with definite AIH attending during the same period, the non-EC patients were younger (p<0.05), presented with cholestatic biochemistry (p=0.014), and morphological biliary features more frequently (p<0.0005) and showed a poorer initial response to standard therapy (p<0.0005).
CONCLUSIONS: Clinical expression of AIH in non-EC patients seems to differ in important respects from that in EC or Japanese patients. Management of such patients is challenging and may require alternative or more aggressive treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11950822      PMCID: PMC1773189          DOI: 10.1136/gut.50.5.713

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  35 in total

1.  Pharmacokinetic characteristics of methylprednisolone in Korean renal transplant recipients.

Authors:  C M Kang; J H Ahn; K W Kahng; J S Kang; I C Shin; J Y Kwak
Journal:  Transplant Proc       Date:  1999-11       Impact factor: 1.066

2.  Autoimmune hepatitis: the investigational and clinical challenges.

Authors:  A J Czaja; M P Manns; I G McFarlane; J H Hoofnagle
Journal:  Hepatology       Date:  2000-05       Impact factor: 17.425

Review 3.  Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis.

Authors:  A J Czaja; P T Donaldson
Journal:  Immunol Rev       Date:  2000-04       Impact factor: 12.988

4.  In vitro response to immunosuppressive agents in blacks.

Authors:  M Ward; V A Lazda; P J Gaddis; B M Stormoen; Y Smith; A J Fabrega; R Pollak
Journal:  Transplant Proc       Date:  1993-08       Impact factor: 1.066

5.  Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system.

Authors:  M Kaya; P Angulo; K D Lindor
Journal:  J Hepatol       Date:  2000-10       Impact factor: 25.083

6.  Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors.

Authors:  P T Donaldson; D G Doherty; K M Hayllar; I G McFarlane; P J Johnson; R Williams
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

7.  Racial origin and its effect on disease expression and HLA-DRB1 types in patients with rheumatoid arthritis: a matched cross-sectional study.

Authors:  B Griffiths; R D Situnayake; B Clark; A Tennant; M Salmon; P Emery
Journal:  Rheumatology (Oxford)       Date:  2000-08       Impact factor: 7.580

8.  Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients.

Authors:  T Seki; K Kiyosawa; H Inoko; M Ota
Journal:  Hepatology       Date:  1990-12       Impact factor: 17.425

9.  Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients.

Authors:  E J Schweitzer; S Yoon; J Fink; A Wiland; L Anderson; P C Kuo; J W Lim; L B Johnson; A C Farney; M R Weir; S T Bartlett
Journal:  Transplantation       Date:  1998-01-27       Impact factor: 4.939

10.  Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability.

Authors:  A Lindholm; M Welsh; C Alton; B D Kahan
Journal:  Clin Pharmacol Ther       Date:  1992-10       Impact factor: 6.875

View more
  21 in total

Review 1.  Advances in the current treatment of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-04-03       Impact factor: 3.199

2.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

Review 3.  Autoimmune Hepatitis in Special Populations: In Pediatrics and Across Different Ethnicities/Races.

Authors:  Nanda Kerkar
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-08-02

4.  Characteristics and outcome of autoimmune liver disease in Asian children.

Authors:  Way S Lee; Su H Lum; Chooi B Lim; Sze Y Chong; Kim M Khoh; Ruey T Ng; Kai M Teo; Christopher C M Boey; Jayalakshmi Pailoor
Journal:  Hepatol Int       Date:  2014-08-06       Impact factor: 6.047

Review 5.  Autoimmune hepatitis.

Authors:  Farhad Sahebjam; John M Vierling
Journal:  Front Med       Date:  2015-03-06       Impact factor: 4.592

6.  Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.

Authors:  Cumali Efe; Haider Al Taii; Henriette Ytting; Niklas Aehling; Rahima A Bhanji; Hannes Hagström; Tugrul Purnak; Luigi Muratori; Mårten Werner; Paolo Muratori; Daniel Klintman; Thomas D Schiano; Aldo J Montano-Loza; Thomas Berg; Fin Stolze Larsen; Naim Alkhouri; Ersan Ozaslan; Michael A Heneghan; Eric M Yoshida; Staffan Wahlin
Journal:  Dig Dis Sci       Date:  2018-03-22       Impact factor: 3.199

7.  Management of patients with difficult autoimmune hepatitis.

Authors:  Richard Parker; Ye Htun Oo; David H Adams
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

Review 8.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

Review 9.  Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly.

Authors:  Albert J Czaja
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

10.  Autoimmune hepatitis in a North American Aboriginal/First Nations population.

Authors:  G Y Minuk; S Liu; K Kaita; S Wong; E Renner; J Rempel; J Uhanova
Journal:  Can J Gastroenterol       Date:  2008-10       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.